Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Cash & Equivalents (2021 - 2025)

Core Scientific's Cash & Equivalents history spans 5 years, with the latest figure at $453.4 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 79.2% year-over-year to $453.4 million; the TTM value through Sep 2025 reached $453.4 million, up 79.2%, while the annual FY2024 figure was $836.2 million, 1558.83% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $453.4 million at Core Scientific, down from $581.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $836.2 million in Q4 2024 and bottomed at $1.6 million in Q3 2021.
  • The 5-year median for Cash & Equivalents is $96.1 million (2024), against an average of $189.9 million.
  • The largest YoY upside for Cash & Equivalents was 6186.29% in 2022 against a maximum downside of 86.52% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $117.9 million in 2021, then crashed by 86.52% to $15.9 million in 2022, then surged by 217.36% to $50.4 million in 2023, then surged by 1558.83% to $836.2 million in 2024, then plummeted by 45.78% to $453.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Cash & Equivalents are $453.4 million (Q3 2025), $581.3 million (Q2 2025), and $697.9 million (Q1 2025).